Diabetes Outcome Study
Study Description and Methods
In this study, we wanted to describe how primary care clinicians care for patients with type 2 diabetes. This was a descriptive study of predictors of glycemic control of patients with type 2 diabetes mellitus. Physicians from the Minnesota Academy of Family Physicians Research Network (MAFPRN) and two networks in Texas also participated.
Specific Aims and Objectives
Our specific aims were:
- To describe the outcomes of type 2 diabetes achieved by primary care physicians and their patients; and
- To identify the major patient, physician and practice characteristics that are associated with varying levels of glycemic control and health-related quality of life indicators.
Timeline
This study was conducted from February 2001 through April 2002.
Status
This project is closed. See below for Key Findings and Publications!
Contact Information
For additional information about this study, please contact:
James Galliher, PhD
Research Director
AAFP National Research Network
1-800-274-2237 x3120
jgallihe@aafp.org
James Galliher, PhD
Research Director
AAFP National Research Network
1-800-274-2237 x3120
jgallihe@aafp.org
Presentations
S.J. Spann, J.M. Galliher, R.J. Volj, J. Hickner. “Diabetes Outcome Study: Final Report and Presentation”. Eli Lilly and Company, Indianapolis, IN. Oct 10, 2002.
Stephen J. Spann, MD. “Diabetes Outcome Study: Physician and Patient Characteristics”. NAPCRG Presentation.
Robert J. Volk, PhD. “The Diabetes Outcome Study: A Progress Report”. Convocation 2002.
Stephen J. Spann, MD. “Diabetes Outcome Study: Physician and Patient Characteristics”. NAPCRG Presentation.
Robert J. Volk, PhD. “The Diabetes Outcome Study: A Progress Report”. Convocation 2002.
Key Findings and Publications
Only modest numbers of patients achieve established targets of diabetes control. Reengineering primary care practice may be necessary to substantially improve care.
Access the complete manuscript:
Access the complete manuscript:
This study was funded by grants from Eli Lilly and Company.
